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ABSTRACT: This paper describes the effects of immune genes genetic variants and mRNA 
expression on depression‘s risk, severity, and response to antidepressant treatment, through a 
systematic review on all papers published between 2000 and 2016. Our results, based largely 
on case-control studies, suggest that common genetic variants and gene expression pathways 
are involved in both immune activation and depression. The most replicated and relevant 
genetic variants include polymorphisms in the genes for interleukin (IL)-1b, IL-6, IL-10, 
monocyte chemoattractant protein-1 (MCP-1), tumor necrosis factor-alpha (TNF-a), C-reactive 
protein (CRP) and phospholipase A2 (PLA2). Moreover, increased blood cytokines mRNA 
expression (especially of IL-1b) identify patients that are less likely to respond to conventional 
antidepressants. However, even for the most replicated findings there are inconsistent results, 
not only between studies, but also between the immune effects of the genetic variants and the 
resulting effects on depression. We find evidence that these discrepant findings may be 
explained, at least in part, by the heterogeneity of the depression immunophenotype, by 
environmental influences and gene X environment interactions, and by the complex interfacing 
of genetic variants with gene expression. Indeed, some of the most robust findings have been 
obtained in patients developing depression in the context of treatment with interferon-alpha, a 
widely used model to mimic depression in the context of inflammation. Further ‗omics‘ 
approaches, through GWAs and transcriptomics, will finally shed light on the interaction 
between immune genes, their expression, and the influence of the environment, on the 
pathogenesis of depression. 
Key words: Inflammation; Depression; Genes; Gene Expression; Polymorphisms; Immune 
activation; Cytokines; Enzymes; Transcriptomics 
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INTRODUCTION  
 
Depression presents a clinical puzzle, affecting individuals in a multitude of differing ways 
(Pariante and Nemeroff, 2012). Antidepressants can treat depression, but with varying efficacy 
(Pigott et al., 2010). The condition is both hereditary and environmental (Sullivan et al., 2000). 
The biological mechanisms behind these discordant features remain elusive, frustrating our 
ability to address it. A solution may come from an interplay between the immune system and 
depression (Pollak and Yirmiya, 2002; Zunszain et al., 2011).  
 
Some depressed patients express higher levels of cytokines, the messengers of the immune 
system, while the administration of cytokines themselves can cause depression. Many studies 
have reported increased levels of inflammatory cytokines and their receptors in the peripheral 
blood and cerebrospinal fluid (CFS) of patients with major depression. In addition, patients with 
major depression have been found to exhibit elevations in peripheral blood concentrations of 
acute phase proteins, chemokines, adhesion molecules, and inflammatory mediators such as 
prostaglandins. These findings have been reviewed extensively before (Raison et al., 2006; 
Dantzer et al., 2008; Liu et al., 2012; Valkanova et al., 2013; Miller and Raison, 2015).  
 
One hypothesis posits that this co-occurrence of depression and inflammation derives from the 
need for a rapid, preemptive inflammatory response following stress, which was life-saving 
during ancestral times when infection was often fatal (Miller and Raison, 2015). Inflammation 
may also have occurred when an individual felt threatened by another, since that physical attack 
may open up a route for infection. These ancestral mechanisms are visible in the fact that both 
depression and immune activation can result from social conflict, through activation of the 
inflammasome complex (Iwata et al., 2013, Maslanik et al., 2013). Indeed, the behavioral 
features of depression, like social withdrawal, anorexia, anhedonia and hypervigilance, may 
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themselves help the immune system to mount a response to infection, and cytokines induces 
the so-called ―sickness behavior‖, a correlate of the inflammatory response (Peters, A., 2006). 
Taking this further, depression may be a chronic, over-extended version of sickness behavior. 
Indeed, in the developed world medical science has largely contained the infection challenge; 
yet this inbuilt defensive combination of depression and inflammation is still with us, like 
redundant heavy artillery left lying around from an earlier conflict — unwanted, perhaps 
dangerous and hard to shift. One potential explanation for this continuing combination is that 
similar genes are relevant to both immune activation and depression. 
 
Demonstrating a common genetic substrate for depression and immune activation is of 
substantial scientific and clinical interest, and could unveil the mechanisms by which the innate 
immune system and depression intertwine. Indeed, twin studies have shown a hereditable link 
between depression and inflammation (Su et al., 2009). In this review we look at the 
inflammatory genes that shape the nature of depression and, in particular, the polymorphisms 
that accentuate or attenuate this process. While no genetic magic bullet has been found — no 
clearly responsible single nucleotide polymorphism (SNP) such as in sickle cell disease — 
research suggests that individual polymorphisms play a role in the susceptibility to, the degree 
of, and the recovery from, depression (Caspi et al., 2003; Manuck et al., 2004). Studies have 
also begun to unravel the plastic nature of inflammatory genes, particularly the influence of 
adverse childhood events on the immune system and later susceptibility to depression 
(Baumeister et al., 2015). More recently, Genome-Wide Association Studies (GWAS) have been 
employed to elicit candidate genes for depression. GWAS have had some spectacular results in 
other pathologies such as diabetes and rheumatoid arthritis (Hardy and Singleton, 2009), but 
have had limited success so far with depression. Finally, gene expression studies and 
transcriptomics have begun to complement and supplant GWAS in whole genome investigation. 
Gene expression studies have begun to trace out networks of genes with links to inflammation 
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involved in depression pathogenesis, and improving technology, such as RNA-seq, have 
allowed wider and more sensitive investigations than the previous gold-standard gene 
expression microarrays (Hepgul et al., 2013). A new picture of networks and pathways 
connecting behavior and the immune system is being uncovered. 
 
 
METHODS  
 
This review encompasses the literature published between 2000 and 2016. We limited our 
review to these years to best showcase current thinking about the genetic relationship between 
immune activation and depression, and to include studies employing the most up-to-date 
methods. We build on, and extend, our previous review on this topic (Bufalino et al., 2013). We 
focus on the relationship between genetic polymorphisms of immune genes and depression‘s 
risk, severity, and response to antidepressant treatment, including Major Depressive Disorder 
(MDD), Recurrent Depression, Dysthymia, Childhood Onset Major Depression and Geriatric 
Depression. In addition, we have included studies examining the prevalence of depression in 
subjects with medical illnesses, such as cardiac diseases, cancer, and those receiving cytokine 
therapy like interferon-alpha (IFN-α).  
 
The literature reviewed was identified through the following sources: PubMed, The Cochrane 
Library, Scopus Embase, Ovid of Medline, PsycINFO and ISI web of Knowledge. We 
considered case-control, prospective, twin/family-based association and genome-wide 
association studies. In addition we included pharmacogenetic studies to better understand the 
mechanisms involved in the relationship between immune activation and depression in relation 
to antidepressant response, and gene expression studies as both candidate genes and 
transcriptomics. Keywords included the following: ‗‗gene‘‘ or ‗‗genes‘‘ or ‗‗single nucleotide 
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polymorphisms‘‘ or ‗‗SNPs‘‘; ‗‗depression‘‘ or ‗‗depressive disorder‘‘; and ‗‗inflammation‘‘ or 
‗‗inflammatory cytokine‘‘ or ‗‗interleukin‘‘ or ‗‗interferon- a treatment‘‘ or ‗‗CRP‘‘. Papers 
concerning animal models were excluded. The search was also limited to English-language 
studies. In total, we examined 113 studies and 4 meta-analyses. Numerous studies have tested 
more than one genetic variant, and are repeatedly cited. 
 
RESULTS  
 
We begin with pro- and anti-inflammatory cytokine genes, T-cell-function genes, and C-reactive 
protein (CRP) gene. We then examine genetic variations in enzymes involved in immune 
activation and oxidative stress. Finally, we examine results from Genome Wide (GWAS) and 
gene expression studies. 
 
Interleukin-1 beta (IL-1b) 
The IL-1b gene is highly polymorphic, with the -511 C/T variation (rs16944) a particular target of 
study. The first study of the -511T polymorphism was conducted by Yu et al., (2003a) who found 
that a subgroup of MDD patients homozygous for the ‗low-producing‘ 511C allele had higher 
depressive symptom severity and a less favorable response to fluoxetine treatment when 
compared with 511T carriers. Tadic et al. (2008) then demonstrated that the C/C genotype 
showed a slower and less pronounced response to paroxetine than patients with the C/T or T/T 
genotype. No association was found between the 511T gene variant and mirtazapine treatment 
response (Tadic et al., 2008). In a Chinese population (Hwang et al., 2009), depressed patients 
carrying the C/C genotype showed a significantly earlier age of onset of depression compared 
with depressed subjects who were C/T heterozygous or homozygous for the T allele. Similar 
findings were also reported in dysthymic patients, who had a higher prevalence of the 511C 
allele compared with controls (Fertuzinhos et al., 2004).  
©    2016 Macmillan Publishers Limited. All rights reserved.
  
 
In contrast, an association was found between the ‗high-producing‘ T variant and depressive 
symptoms in subjects with Alzheimer‘s disease (McCulley et al., 2004) and schizophrenia (Rosa 
et al., 2004). Kim et al (2013a) found the T/T form of IL-1b -511 to be associated with 
depression at baseline and one-year follow-up in breast cancer patients. However, in a 
Taiwanese sample, this was not associated with MDD (Chi et al., 2011). 
 
The variance of these polymorphic effects in the 511 SNP may depend on exposure to early life 
stress. A study of 1053 caucasian Hungarians volunteers (Kovács et al., 2016a) found that the 
presence of the A allele of rs16944 (equivalent to T 511), when paired with childhood 
maltreatment, leads to increased depressive and anxiety symptoms in adult life. However, the 
same SNP confers a weak protective effect against depressive symptoms (but not anxiety) 
when the individual is exposed to life stressors as an adult (and has not experienced with 
childhood maltreatment). A paper by Tartter et al. (2015) examined the 511 variations in a study 
of 444 Australian youths. The C allele was associated with greater depressive symptoms 
following interpersonal stress. The same result was not found following exposure to other 
stressors, such as negative health and work events, and the depressive symptoms did not occur 
until after 20 years of age, leading the authors to theorize that the genetic effects of exposure to 
adverse childhood events only manifest in late adolescence. 
 
Recently, in addition to 511(C/T), a polymorphism in the promoter region of the IL-1b gene at 
position 31(T-31C substitution, located in a TATA-box motif of IL-1b) has been investigated in 
patients with major recurrent depression. Correspondence analysis revealed that a combination 
of genotype T/T for polymorphic site 31 and genotype C/C at position 511 is associated with 
depression, while controls presented a heterozygous combination at both polymorphic sites 
(Borkowska et al., 2011). Instead, no clear evidence has been found in childhood depression 
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(Misener et al., 2009, 2008) or geriatric depression (Luciano et al., 2010).  In a study of 599 
Caucasian lung cancer patients, Reyes-Gibby et al (2013a) found an association between IL-1B 
T-31C and a symptom cluster of pain, depressed mood and fatigue. 
 
In a sample of 256 MDD patients, three SNPs located within regulatory regions of the IL-1b 
gene were investigated: 3953 C/T (rs1143634) in exon 5, rs1143643(A/G) in intron 6, and the 
aforementioned rs16944(A/G) in the promoter region. Additionally, this study also evaluated 
whether any of these SNPs were associated with antidepressant treatment response and neural 
substrates of emotion processing. They found a significant association between the G/G 
genotype of rs16944 (same as CC 511) and G/G genotype of rs114643 with non-remission after 
6 weeks of antidepressant treatment. Interestingly, functional magnetic resonance imaging 
(fMRI) showed that, in a subgroup of patients, the same genetic variants are associated with 
reduced responsiveness of the amygdala and the anterior cingulate cortex (ACC) to emotional 
stimulation (Baune et al., 2010). The 3953 C/T (rs1143634) polymorphism was investigated also 
in subjects with post-stroke depression however, with negative findings (Kim et al., 2011). A 
paper on 773 elderly Koreans (Kang et al., 2014) also found a significant association between 
IL-1b 3953C/T and depression, however this association was lost once a Bonferroni correction 
was applied. In another study, the IL-1b SNP rs1143643 does not enhance depressive 
symptoms when combined with childhood trauma. However, the minor A allele does provide 
protection against depression due to trauma in adult life (Kovács et al., 2016a). This same allele 
was previously associated with a better response to anti-depressant therapy (Baune et al., 
2010). 
 
Finally, Ridout et al (2014) examined 198 ethnically-diverse American children ages 3-5 
exposed to maltreatment in the preceding 6 months. They found an association between 
rs1143633 AA genotype and greater symptoms of major depressive disorder when exposed to 
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contextual stressors, such as loss, instability or poverty. However, the study was limited by 
having only a small number of children homozygous for AA. 
 
Interleukin-1 receptor antagonist (IL-1Ra)  
In two different studies, no significant associations were found between childhood depression 
(Misener et al., 2008), or antidepressant response to paroxetine and mirtazapine in MDD 
patients (Tadic et al., 2008), and IL-1Ra (86 bp) polymorphism. Only one study has found that 
this polymorphism confers a susceptibility to develop dysthymia in Brazilian patients 
(Fertuzinhos et al., 2004).  
 
Interleukin-1 receptor, type I 
Doong et al (2014) found no association between ILR1 and a symptom cluster of pain, sleep 
disturbance, fatigue and depression. 
 
Interleukin-1 receptor type 2 (IL-1R2) 
A haplotype (A1) consisting of three SNPs (rs4141134, rs11674595, rs7570441) of IL-1R2 was 
found to be associated with subsyndromal depression in a study of 167 oncology patients and 
caregivers in the US (Dunn et el al., 2013). IL-1R2 is a decoy cytokine receptor that binds IL-1B. 
The study theorized that reduced expression of IL-1R2 leads to an excess of IL-1B, accounting 
for depressive symptomatology. 
 
 
Interleukin-4 (IL-4)  
Kim et al have substantially investigated this anti-inflammatory interleukin. They found a 
significant association between post-stroke major depression and the ‗low producing‘ C/C 
genotype of the +33T/C IL-4 polymorphism (Kim et al., 2011), but no association among breast 
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cancer patients and depression (Kim et al., 2013a). Moreover, they found that subjects with the 
+33C allele show a relationship between increasing numbers of physical disorders and incident 
late-life depression (Kim et al., 2013b).  
 
Illi et al. (2012) found evidence for the involvement of the rs2443248 (T/G) SNP among a group 
of oncology patients, with the minor G allele associated with worse depression, fatigue, sleep 
and pain.  
 
Interleukin-6 (IL-6)  
Il-6 has been one of the most investigated interleukins due to its high association with 
depression (Liu et al., 2012, Valkanova et al., 2013), though this association is not without 
dispute (Chocano-Bedoya et al., 2014). IL-6 is secreted largely by monocytes and macrophages 
peripherally, and by astrocytes and microglia in the CNS. In several different studies, no 
significant associations were found between MDD, childhood depression or post-stroke 
depression, and either of the polymorphisms at position 634 or at position 174 of the IL-6 gene 
(Clerici et al., 2009; Hong et al., 2005; Misener et al., 2008, 2009). However, in a prospective 
study in patients receiving pegylated (PEG) interferon-alpha (IFN-α) and ribavirin treatment for 
hepatitis C virus (HCV) infection, Bull et al. (2009) found that the functional G-174C 
polymorphism (rs1800795) in the promoter region of the IL-6 gene predicted depressive 
symptoms but not fatigue. Carrying two copies of the ‗high IL-6‘ G allele polymorphism was 
associated with a marked increase in depressive symptoms compared with the ‗low IL-6‘ C 
allele (Bull et al., 2009). This finding was later replicated by Udina et al (2013), who again found 
that carrying the CC genotype of rs1800795 is associated with less severe interferon-alpha-
induced depression. 
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On the contrary, Kovács et al (2016b) found that, in the presence of stressful life effects, the risk 
of depression was higher in those homozygous for the low-producing C allele (rs1800795). 
However, they caution this effect may be part of a wider haplotype, exerting its effects in a non-
independent manner on gene expression. Tartter et al (2015) also found that CC carriers for IL-
6 174 were more likely to experience depressive symptomatology following chronic 
interpersonal stress, but not other stressors. They also noted that 174G confers protection 
against inflammation in adolescence, but increases the risk for inflammation in adulthood, 
possibly indicating an age-dependent function. Roetker et al (2012) found that women 
homozygous (CC/GG) for rs1800795 had an increased risk of depression, but only in the 
presence of other risk genes. 
 
In a study of 398 female breast cancer patients, Doong et al (2014) also reported an association 
between patients homozygous for the high-producing G allele of IL-6 (rs2069845) and a 
symptom cluster of pain, fatigue, sleep disturbance and depression, potentially occurring as an 
interaction between SNPs for IL-13 and TNF-alpha. In another study of breast cancer patients 
(Saad et al., 2014), being homozygous for the G allele of rs2069840 was associated with 
subsyndromal depression. 
 
Interleukin-8 (IL-8)  
IL-8 is involved in neutrophil recruitment. A polymorphism of the IL-8 gene at position 251(T/A) 
was investigated in subjects with post-stroke depression, with negative findings (Kim et al., 
2011). Kim et al (2013a) also investigated IL-8-251T/A in breast cancer patients and again 
found no association between either of the alleles and depression. The same research team 
later found that a relationship between increasing numbers of physical disorders and incident 
late-life depression is present in those with the IL-8 251A variant in the aforementioned study 
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(Kim et al., 2013b). Kang et al (2014) however found no association between IL-8 −251T/A and 
depression in a study of 732 elderly Koreans. 
 
In an examination of a symptom cluster of pain, fatigue and depression in lung cancer (Reyes-
Gibby et al., 2013b), patients with the low-producing T/T polymorphism of IL-8 251 were more 
likely to experience severe depression but less susceptible to pain or fatigue. 
 
Interleukin-10 (IL-10)  
IL-10 is an anti-inflammatory cytokine. A study investigating a polymorphism at position 819 in 
IL-10 found no evidence of an association with MDD (Jun et al., 2002). Similarly, no 
associations were found in another study looking at childhood depression and the 819(C/T), 
1082(G/A) or 592(C/A) polymorphisms (Misener et al., 2008); and no associations were found in 
patients with a single depressive episode, with or without stressful life events prior to onset 
(Haastrup et al., 2012).  
 
On the other hand, in a study of patients affected by bipolar disorder (type I or II) or MDD, an 
association was found between the polymorphism at position 1082(G/A) and MDD (Clerici et al., 
2009). Specifically, the ‗low IL-10 producing‘, A/A genotype, was significantly more frequent in 
MDD patients than in controls. Similar results were reported by Kim et al. (2011) who found a 
significant association between post-stroke depression and the A allele-A/A genotype of the 
same polymorphism (Kim et al., 2011). A further study conducted in patients with end stage 
renal disease also confirmed these findings (Holtzman et al 2012).  
 
No association was found between IL-10 1082 G/A alleles (rs1800896) and depression (Kang et 
al., 2014) in a study of 732 elderly Koreans. Similarly, 1082 G/A did not correlate with 
depression in breast cancer patients (Kim et al., 2013a) or in the relationship between physical 
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health and incident late-life depression (Kim et al., 2013b). Continuing the negative findings, 
1082 G/A was not associated with late onset depression in a study of elderly Brazilians (Torres 
et al., 2014). However, in a study of more than 900 elderly Americans (Rana et el., 2014), 
rs1800896 was found to be associated with optimism when present in a multi-gene locus with 
MAO-α and Fibrinogen gamma chain (FGG) SNPs. 
 
Contradictory findings on the genetic association between depression and IL-10 have been 
found by analyzing SNPs of the genomic region of the IL-10 gene cluster. Traks et al. (2008) 
found that the frequency of the T–G–C haplotype, containing SNPs from IL-20 and IL-24 genes, 
is higher among patients with MDD compared to controls (Traks et al., 2008). However, Koido 
and colleagues (2009) did not confirm these results in patients with a diagnosis of MDD and 
panic disorder. Instead, they found strong allelic and genotypic associations between both 
diagnoses and a polymorphism in the gene of an inhibitor of kappa light polypeptide gene 
enhancer in B-cells kinase epsilon (IKBKE), with a stronger association with panic disorder 
(Koido et al., 2009).  
 
IL-10 rs1518111 was investigated in a study of 167 oncology patients and caregivers (Dunn et 
al., 2013) and the rare A/A configuration found to be associated with subsydromal depression. 
This non-coding SNP has an unknown function but has previously been linked with Behçet‘s 
Disease. 
 
Interleukin-10 Receptor B (IL-10RB)  
No association was found between the IL-10RB polymorphism rs2834167 and depression in 
lung cancer patients (Reyes-Gibby., 2013b) but Lys47Glu (rs2834167) was associated with a 
symptom cluster of pain, depressed mood and fatigue when combined with other mutant alleles 
(Reyes-Gibby., 2013a). 
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Interleukin-11 (IL-11)  
An important genome-wide pharmacogenetic study, in a large sample of MDD patients treated 
with antidepressants, found that the major alleles of SNP rs1126757 in the gene encoding IL-11 
and of SNP rs7801617 in the IL-6 gene (C and G, respectively) predict a worse antidepressant 
response (Uher et al., 2010). Powell et al. (2013a) found that carriers of the A allele of 
rs1126757 have greater reduction in IL-11 mRNA levels in response to escitalopram treatment, 
and that this reduction is associated with clinical response, thus indicating a potential 
mechanism by which genetic variants and gene expression interact in conferring a behavioral 
phenotype.  
 
Interleukin-13 (IL-13) 
One study (Doong et al., 2014) among 398 breast cancer patients prior to surgery found that the 
A allele of IL-13 (rs1295686) was associated with a symptom cluster of pain, fatigue, sleep 
disturbance and depression. This anti-inflammatory cytokine has a well-established link with 
asthma. 
 
Interleukin-17 
In the same study as above (Doong et al., 2014) IL-17 was not associated with the cluster. 
 
Interleukin-18 (IL-18)  
Haastrup et al. (2012) investigated polymorphisms of the IL-18 gene in depressed patients with 
or without stressful life events prior to depression. The authors examined two promoter SNPs, at 
position 607(G/T) and at position 137(C/G). They found that the major alleles of both 
polymorphisms (G and C, respectively) increase the risk of depression in subjects with previous 
stressful life events, but not in those without. In addition, there was a tendency for higher 
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plasma IL-18 levels among depressed patients who were G/G homozygous at position 607 and 
C/C at position 137. 
 
Interleukin-28 beta (IL-28-b)  
A polymorphism (rs1297860 C/T) in the IL-28b gene, normally associated with viral response in 
HCV patients during IFN-α treatment, has been studied by Lotrich et al. (2011) in relationship 
with psychiatric symptoms in patients taking IFN-α treatment. They investigated whether this 
polymorphism could be related to depression, fatigue, sleep problems, and/or changes in 
appetite. The C allele was associated with better viral clearance, loss of energy, worsened 
sleep, and a change in appetite, but not with depression (Lotrich et al., 2011).  
 
Colony stimulating factor 2 receptor beta (CSF2RB)  
A recent study has tested the association between SNPs of the CSF2RB gene and three major 
mental disorders (bipolar affective disorder, schizophrenia and MDD) in the Chinese Han 
population. Chen et al. (2011) found that two haplotypes, composed of three SNPs (rs2284031, 
rs909486 and rs738149), were strongly associated with schizophrenia and MDD. The T–C–A 
haplotype represented a risk haplotype while the C–T–G was a protective haplotype. In addition, 
the rs738149 SNP was significantly associated with MDD, and rs2284031 with both MDD and 
schizophrenia (Chen et al., 2011).  
 
Interferon-gamma (IFN-gamma) 
Among many functions, Interferon gamma activates indoleamine 2,3 dioxygenase (IDO), an 
enzyme that metabolises the serotonin-precursor, tryptophan, and increases depressogenic 
tryptophan metabolites. The IFN-gamma gene has a variable length CA repeat in its first intron. 
Myint et al (2013) found that individuals homozygous for the CA repeat allele 2 had higher levels 
of serum kynurenine at baseline, a by-product of tryptophan metabolism. Following treatment 
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with a wide range of therapies (selective serotonin reuptake inhibitor antidepressant, 
psychological therapy and electroconvulsive treatment) depressed individuals either 
homozygous or heterozygous for the same allele also had greater tryptophan breakdown and 
higher serum kynurenine. 
 
Oxenkrug et al. (2011) compared the IFN-gamma +874(T/A) polymorphisms in HCV patients 
with or without IFN-α-induced-depression (rs2430561). The results demonstrated that the ‗high 
producing‘ T allele increases the risk of IFN-α-induced depression (Oxenkrug et al., 2011). 
However, in another study, Clerici et al. (2009) did not find any differences for genotype or allele 
distribution of +874 IFN-gamma in MDD patients (Clerici et al., 2009).  
 
Interferon-gamma receptor 1 (IFNGR1) 
Saad et al (2014) reported an association between subsyndromal depression and the rare A 
allele of rs9376268 in breast cancer patients. 
 
Interferon-alpha receptor (IFNAR1)  
Examining the role of the IFN-α receptor (IFNAR1) gene in an American sample with HCV, one 
study found that the 5/5 or 5/14 genotype of a G/T repeat dinucleotide microsatellite 
polymorphism within the promoter region is associated with a larger increase in depressive 
scores during IFN-α treatment, and with a superior antiviral activity. Furthermore, only patients 
with the 5/14 genotype were found to show an association with increased somatic and 
neurovegetative symptoms (Yoshida et al., 2005).  
 
Monocyte chemoattractant protein-1 (MCP1)  
MCP1 is known to attract peripheral monocytes to the brain, resulting in an inflammatory 
reaction; it is also known as chemokine (C-C motif) ligand 2 (CCL-2). Two case-control studies 
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have investigated the role of the G-2518A polymorphism, and all have found that the A allele is 
associated with an increased risk of psychopathology. In a Korean population, subjects with the 
A allele were found to have an increased risk of developing both MDD and psychotic features 
compared with those with the G allele (Pae et al., 2004b). Moreover, in a clinical sample of 96 
Italian outpatients with MDD and bipolar disorder, a higher frequency of the A/A genotype and of 
the A allele was observed in subjects affected by bipolar disorder; moreover, bipolar disorder 
subjects with the A/A genotype had a higher number of suicide attempts and more frequent 
psychotic symptoms (Altamura et al., 2010). Interestingly, the A allele is considered the ‗low 
producing‘ (Rovin and Saxena, 1999), and we have recently shown that low serum levels of 
MCP1 predict lack of response to antidepressants (Carvalho et al., 2013).  
 
Tumor necrosis factor-alpha (TNF-α) 
A Korean study demonstrated that the ‗high producing‘ A allele and the A/A genotype of the G-
308A TNF-α (rs1800629) polymorphism are significantly associated with an increased risk of 
MDD (Jun et al., 2003b). In another study, the TNF-α 308A allele was also found to be 
associated with post-stroke depression (Kim et al., 2011). However, opposite results were found 
by Clerici et al. (2009) who observed a different allele distribution of G-308A TNF-α among a 
sample of 84 Italian outpatients affected by bipolar disorder or MDD. In particular, the 
percentage of A carrying subjects is lower in subjects with MDD (Clerici et al., 2009). Another 
study looking at individuals with late-life MDD found that subjects affected by MDD have a 
higher percentage of the G/G genotype than G/A genotype (Cerri et al., 2009). None of the 
patients were found to have A/A genotype. In a study of 167 oncology patients (Dunn et al., 
2013) individuals with the rare A allele are less likely to suffer from clinically significant levels of 
depression. In yet another study, in patients with a single depressive episode with or without 
stressful life events prior to MDD, no involvement was found for the TNF-α SNPs 308(G/A) and 
238(G/A) (Haastrup et al., 2012). This finding is in line with reports from Misener and colleagues 
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(2008) who found no significant association with childhood depression and these same TNF-α 
polymorphisms, or two others in the promoter region at positions 1031(T/C) and 857(C/T) 
(Misener et al., 2008). Among 444 Australian youth, TNF-α 308G/A was not found to moderate 
depressive symptoms following chronic interpersonal stress exposure (Tartter et al., 2015). 
Finally TNF-α 308G/A was not found to contribute to depression in breast cancer patients (Kim 
et al., 2013a). We identified one further study concerning the TNF-α A-308G polymorphism 
(rs1800629) in relation to IFN-α- induced depression: the authors found a significant association 
with labile anger and fatigue but not with depression (Lotrich et al., 2010).  
 
A further polymorphism at position -850(C/T) was investigated, in post-stroke depression with 
negative findings (Kim et al., 2011). The same team assessed 850 (C/T) in a later study (Kim et 
al., 2013a) and found an association between 850T and depression, though with deviation from 
the Hardy-Weinberg equilibrium. Kim et al also found, in the aforementioned study (2013b), that 
the relationship between increasing numbers of physical disorders and incident late-life 
depression is present in those with the 850 T allele.  
 
The less-well investigated TNF-α SNP rs1800610 was associated with a cluster of fatigue, sleep 
disturbance and depression in breast cancer patients when carrying one or both of the rare T 
alleles (Doong et al., 2014). The SNP potentially worked in conjunction with IL-6 and IL-13 
variations to manifest this symptom cluster. 
 
Lastly, a genome-wide association study (GWAS) found support for the involvement of TNF-α 
rs769178 polymorphism. In a sample of 1738 MDD patients, 57 genes were identified and 92 
SNPs mapped. The TNF-α rs769178 was the only gene found to be related to depression, and 
it remained significant after correcting for multiple testing. However, the authors specified that 
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given the large number of candidate SNPs and genes that were tested, even this significance 
may well be a false positive (Bosker et al., 2010).  
 
Tumor necrosis factor-beta (TNF-b) 
Also known as lymphotoxin-alpha, one study investigated the role of the TNF-b gene 
polymorphism at position +252(G/A) in the first intron (chromosome 6) regarding susceptibility to 
MDD, but no associations were found (Jun et al., 2003a). However, Dunn et al (2013) found an 
association between the rare A allele of TNF-b rs2229094 and subsyndromal depression. 
 
Tumor necrosis factor receptor 2 
In another study of lung cancer patients (Reyes-Gibby et al., 2013a), TNFR2 Met196Arg 
(rs1061622) was associated with a symptom cluster of pain, depressed mood and fatigue. 
 
T-cell function related polymorphisms  
The dysregulation of the ubiquitin–proteasome system, the main mechanism for protein 
catabolism, has been a recent and interesting development. A study by Wong et al. (2008) 
found that two untranslated regions (UTRs) SNPs critical for antigen processing and T-cell 
differentiation in proteasome b4 subunit (PSMD4; rs2296840) and in T bet (TBX2; rs17244587), 
T and A, respectively, are significantly associated with MDD (Wong et al., 2008). Moreover, the 
same study described four further polymorphisms relevant to T cell function that are associated 
with antidepressant response: rs2231449 in the CD3 antigen epsilon subunit (CD3E) gene, 
rs34095 in the protein kinase C substrate heavy chain (PRKCSH) gene, rs1043307 in the 
proteasome 26S non-ATPase subunit 9 (PSMD9) gene, and rs3809758 in the signal transducer 
and activator of transcription 3 (STAT3) gene, with the at risk allele being, respectively, A, T, G 
and G. Wong et al also found that the A allele of PSMD13 (rs3817629) is associated with 
response to fluoxetine in MDD. This SNP was further investigated by Minelli et al (2015) who 
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found that each G allele increases the risk for treatment resistant depression. They did not find 
an association between the PSMD9 SNP rs1043307 and treatment response, though did note a 
small association between the A allele of rs1043307 and anxiety disorders in MDD patients. 
 
C-reactive protein (CRP) related polymorphisms  
CRP meta-analysis have identified this protein‘s link with depression (Valkanova et al., 2013), 
though this remains a contentious result (Wium-Andersen et al., 2014).  
 
Halder et al. (2010) examined the effects of three common CRP polymorphisms, 
rs1417938(A/T), rs1800947(C/G) and rs1205(C/ T), on depressive symptomatology and 
circulating CRP levels in 868 healthy individuals. The authors generated three-locus haplotypes, 
and found the T–G–C haplotype to be associated with CRP levels and the A–G–T to show a 
marginal association. Neither single loci nor haplotypes were related to depressive symptoms. 
However, higher depression scores were positively associated with CRP levels among 
individuals with the A–G–T haplotype (Halder et al., 2010).  
 
In a large sample of older men, a cross-sectional study by Almeida et al. (2009) hypothesized 
that two further CRP polymorphisms, rs1130864(C/T) and rs1205(G/A), were associated with 
higher and lower plasma CRP levels respectively, and may influence symptoms of depression. 
The results showed that 5% of participants had significant depressive symptoms, and these 
individuals indeed had higher serum concentrations of CRP. However, although the T allele of 
the rs1130864 SNP was associated with an increase in serum concentrations of CRP, it was not 
associated with an increase in the risk of depression. Instead, the rs1205(G/A) polymorphism, 
which was associated with lower concentrations of serum CRP, was associated with an 
increase in the risk of depression (Almeida et al., 2009). Of note, however, another study 
conducted in two elderly cohorts showed differing results. In one cohort assessed at age 70, the 
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‗high producing‘ T allele of rs1130864 and the ‗low producing‘ A allele of rs1205 were related 
with anxiety and neuroticism in women only; and in the second cohort, assessed at age 87, the 
rs1800947 was found to be associated with depression (Luciano et al., 2010).  
 
Two studies have shown that genetic variations in CRP are associated with depression in the 
context of the metabolic syndrome. In the study mentioned previously regarding the effects of 
variations in the CRP gene on the association between depression and circulating CRP, body 
mass index (BMI) was found to partially account for the moderating effects of the A–G–T 
haplotype on the association between depression and circulating CRP (Halder et al., 2010). 
This suggests that haplotypic variation in the CRP locus moderates an association of 
depressive symptoms with circulating CRP, and this is partially mediated by BMI. A longitudinal, 
population-based study demonstrated that adolescent emotional problems were strongly related 
to the metabolic syndrome among C/C homozygotes, but not among T allele carriers of the CRP 
rs1205 polymorphism (Gaysina et al., 2010).  
 
Ancelin et al (2015) examined five variants of the CRP gene with gender-specific results. 
Women homozygous for the minor allele of rs1205 (TT) were more likely to suffer depression, 
but had lower circulating levels of CRP. The minor alleles of rs1130864 (TT) and rs1417938 
(AA) were protective against depression in women, and were associated with lower levels of 
circulating CRP in men, but not women. In men, no SNP was associated with depression. The 
authors concluded that CRP is not a mediating factor between depression and inflammation and 
cannot not be used as a diagnostic biomarker for depression. They speculated that hormones 
may explain the difference in CRP levels between the sexes.  
 
Rs1417938 was also investigated by Cicchetti et al (2015) who found higher levels of CRP 
among children who had recently experienced maltreatment and carried at least one of the 
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minor A alleles. Lastly, Michopoulos et al (2015) found that rs1130864 was associated with 
increased CRP serum levels in traumatised African-American individuals. 
 
Phospholipase A2 (PLA2)  
Two studies have investigated the potential role of the BanI polymorphism of the cytosolic 
phospholipase A2 (cPLA2) gene in conferring susceptibility to depressive disorder, although 
totaling three independent samples, and all found that the G variant increases the risk of 
psychopathology. In a Korean population, the G variant was associated with an increased risk of 
MDD (Pae et al., 2004a). More recently, Su et al. (2010) have found that the same 
polymorphism influences the risk of developing IFN-α-induced-depression in HCV patients. 
Specifically, the ‗at risk‘ G/G genotype is associated with higher severity of somatic symptoms of 
depression in patients with IFN-α-induced-depression and in a replication sample of patients 
with MDD unrelated to cytokine treatment. Moreover, subjects with this genetic variant had 
lower eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) levels before and during 
IFN-α treatment (Su et al., 2010), indicating a possible mechanism by which genetic variants 
may increase the risk of depression by influencing circulating biomarkers. 
 
Cyclo-oxygenase 2 (COX2)  
A polymorphism in the promoter region of the COX-2-encoding gene, characterized by a G-to-C 
transversion at position 765, has been correlated with recurrent depressive disorder, with the 
G/G homozygote and G allele increasing the risk of depression by 2.5-fold (Galecki et al., 
2010a). This is in line with other findings of genetic variations of the COX2 rs4648308 
polymorphism related with IFN-α- induced depression. Su et al. (2014) found that the ‗at risk‘ A 
allele and the A/G genotype in the COX2 rs4648308 polymorphism significantly increases the 
risk of developing IFN-α-induced depression. In addition, the ‗at risk‘ A/G genotype is associated 
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with lower docosahexaenoic acid (DHA) levels before and during IFN-α treatment (Su et al., 
2010).  
 
Mendlewicz et al (2012) found no association between COX-2 SNPs rs5275, rs20417 and 
resistance, response or remission to antidepressants.  
 
Myeloperoxidase (MPO)  
To our knowledge, only one study has investigated the role of the MPO gene (G-463A 
polymorphism) in the in susceptibility to recurrent depressive disorder. The findings showed that 
the presence of the 463G allele increases the risk of depression by 1.5-fold, whereas in those 
who are homozygous, the risk of depression development increases by 1.7-fold (Galecki et al., 
2010b).  
 
Nitric oxide synthases (NOSs)  
Genetic variants of both inducible (i)NOS and neuronal (n)NOS genes have been related to an 
increased risk of developing depression. In one study, Galecki et al. (2010c) found that the 
functional SNP 1026(C/A), located in the promoter region of the human NOS2A gene, was 
significantly associated with depression risk in a Caucasian sample (Galecki et al., 2010c). 
Furthermore, the same research group found that the presence of the G/G homozygote of the 
NOS2A gene and of the T/T homozygote of nNOS increased the risk of depression (Galecki et 
al., 2011). However, in two previous studies, the functional polymorphism of the nNOS gene 
was not associated with MDD and antidepressant (fluoxetine/fluvoxamine) response in an Asian 
population (Okumura et al., 2010; Yu et al., 2003b).  Galecki et al investigated the NOS2A gene 
again (Galecki et al., 2012) and concluded that the variant is not functional, and was not related 
to expression, though there was an increased mRNA expression of iNOS associated with 
recurrent depressive disorder (see below). 
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Carriers of the minor NOS1 rs2682826 T allele had a higher probability of depression in a study 
of 763 southern Italians (Montesanto et al., 2013). Sarginson et al (2014) examined1222 
individuals undergoing financial stress and found 8 NOS1 SNPs to impact on levels of 
depression. The study also postulated a model that some risk alleles were protective under low 
stress conditions but become risk factors when impacted by life-threatening events.   
 
Kurrikoff et al (2012) found an association between the variants of the NOS promotor nitric 
oxide synthase 1 gene first exon 1f variable number tandem repeat (long and short alleles) and 
depression, but effects varied according to environmental influence and gender. Cheah et al 
(2015) found an association between eight Nitric oxide synthase 1 adaptor protein (NOSAP1) 
polymorphisms and depression in a study of 235 schizophrenics in Australia. This protein has 
previously been strongly associated with schizophrenia, due to down regulation of NO. Lawford 
et al (2013) also investigated 13 NOS1AP SNPs in 121 Vietnam male war veterans with a 
diagnosis of PTSD. They found that the GG genotype of rs386231 was associated with an 
increased severity of depression. 
 
Leukotriene A4 hydrolase (LTA4H)  
Genetic variants in the key enzyme involved in the leukotriene pathway, the leukotriene A4 
hydrolase (LTA4H) gene, have been related to depression in subjects with coronary artery 
disease. Zhao et al. (2009) found a significant protective effect of a novel haplotype in the 
LTA4H gene, named HapE, on coronary artery disease and depression in women, but not men. 
HapE carriers tended to have a lower frequency of coronary artery disease and depression 
compared with HapE non-carriers. The authors indicate that about 7% of the association 
between depression and coronary artery disease severity was explained by HapE (Zhao et al., 
2009).  
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Adhesion molecule related polymorphisms  
Specific polymorphisms of genes related to endothelial dysfunction and platelet aggregation 
have been shown to influence depressive symptoms in cardiac patients. One intronic SNP 
marker, rs216873 within the vonWillebrand factor (vWF) gene, and markers within vascular 
cellular adhesion molecule 1 (VCAM1), were found to be significantly associated with 
depressive symptoms, especially in women with coronary artery disease (McCaffery et al., 
2009). This is the only study that we have identified which examines the role of adhesion 
molecule related polymorphisms. A GWAS study (Kao et al., 2012) specifically looking at 
biological pathways found an association between the cell-adhesion pathway and MDD. 
Specifically, the top four significant pathways were long-term depression, calcium signaling, 
arrhythmogenic right ventricular cardiomyopathy, and cell adhesion molecules. 
 
Indoleamine-2,3-dioxygenase (IDO)  
We are including the IDO gene within the serotonin-related pathway because of the well-known 
link between immune-activation-induced IDO activation, reduction of tryptophan availability, and 
production of depressogenic tryptophan metabolites. IDO is activated by IFN-gamma and TNF-
α. We identified three studies concerning genetic variants of the IDO gene related to IFN-alpha-
induced depression. One found that a polymorphism (rs9657182) in the promoter region of the 
indole-amine-2,3-dioxygenase 1 (IDO1) gene predicts the development of moderate or severe 
depressive symptoms in Caucasian but not in African-American subjects undergoing IFN-alpha 
therapy for HCV infection. Patients who carried the C/C genotype were more likely to exhibit 
moderate or severe depression at week 12 of IFN-alpha treatment compared to those with 
either the C/T or T/T genotypes (Smith et al., 2011). However, a second cross-sectional study, 
conducted in a Brazilian population, found no associations (Galvao de Almeida et al., 2011). 
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Utilising the STAR*D cohort, Cutler et al (2012) discovered two IDO SNPs (rs2929115 and 
rs2929116) that were associated with response to treatment with citalopram. 
 
Genome Wide Association Studies 
Despite great success within other pathologies, GWAS analyses of MDD have struggled to 
produce results at the SNP level. This may be due to various factors, including heterogeneity of 
the condition (e.g., nine accessory symptoms in DSM-5 covering various phenotypes), the need 
for very large sample sizes (10,000 or more cases and controls), influence of the environment 
on causality, and that phenotypes may be the result of the interaction of many risk SNPs, genes 
or pathways, rather than individual polymorphisms. Nevertheless, GWAS studies have 
confirmed some evidence of involvement of immune genes in depression. 
 
As mentioned above, Bosker et al. (2010) conducted a GWAS study that found support for the 
involvement of TNF-α rs769178 polymorphism. In a sample of 1738 MDD patients, 57 genes 
were identified and 92 SNPs mapped; the TNF-α rs769178 was the only gene found to be 
related to depression and that remained significant after correcting for multiple testing. Another 
GWAS (Bosker et al., 2011) identified TNF-a, dendritic nuclear protein-1 (DCNP-1) and 
neuropeptide Y (NPY) as candidate genes. However, a later GWAS (Ripke et al., 2012) 
reported no significant associations with common polymorphisms. Recently, Song et al (2013) 
identified five immune-associated candidate genes that may be associated with MDD: ANPEP 
(degradation of neurotransmitters and IL-8 regulation), ENPEP (regulation of growth and 
differentiation of early B-lineage cells), PRDM1 (a protein that represses beta-interferon gene 
expression), ZBTB32 (may regulate the differentiation and activation of helper T-cells) and 
MMP8 (matrix metalloproteinase-collagen degradation). In one of the largest GWAS studies to 
date (Okbay et al., 2016) subjective well-being was associated with rs3756290, an SNP coding 
for Interferon regulatory factor 1. 
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More recently attention has turned to pathway analysis within GWAS as a means to elucidate 
the causal mechanisms behind MDD. As mentioned above, Kao et al (2012) found that the cell-
adhesion molecule pathway was one of the four most-associated with MDD. They also found 
that both the TNF gene and the IL-1b gene were within 3 different significantly enriched 
pathways. More interestingly, the Cross-Disorder Group of the Psychiatric Genomics 
Consortium (2013) identified calcium channel signalling pathways involved in a wide psychiatric 
phenotype, covering autism spectrum disorder, attention deficit hyperactivity disorder, bipolar 
disorder, MDD and schizophrenia. Altered calcium signalling has been associated with a down-
regulation of TNF-α and inducible nitric oxide synthase (Raison and Miller., 2012).  
 
Gene expression (mRNA) studies/transcriptomics 
As discussed before (Hepgul et al., 2013), peripheral blood mRNA analyses are now a 
consolidated approach for biomarker discovery in mental health, also considering that about 
80% of genes are co-expressed, and similarly modulated at mRNA levels, in peripheral blood 
cells and in brain tissues. A number of studies have used hypothesis-driven approach, with 
candidate immune genes measured in relationship with depression and antidepressant 
response, although most recent work has focussed on transcriptomics analyses, where 
immune-related pathways have figured prominently among the biological systems consistently 
identified. 
 
Candidate gene approach 
Galecki et al, (2012) examined the expression of four genes (PTGS2, MPO, NOS2A, PLA2GA) 
coding for COX-2, MPO, iNOS and secretory phospholipase A2 type IIA, and found them all to 
be increased in patients with recurrent depressive disorder, underlining the role of oxidative and 
nitrosative stress in this condition. 
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Cattaneo et al (2013) examined 9 inflammatory genes for response to antidepressant treatment 
(escitalopram vs. nortryptline) in the GENDEP randomized controlled trial. Depressed patients 
overall have higher levels of IL-1b, IL-6, macrophage inhibiting factor (MIF), and TNF-α, and 
lower levels of the anti-inflammatory cytokine, IL-4, compared with controls. Patients who are 
less responsive to antidepressants also have the highest levels of IL-1b, MIF, and TNF-α, and 
successful antidepressant response is associated with normalization of IL-6 levels. The ability of 
blood IL-1b and MIF mRNA levels to predict antidepressant response has been recently 
replicated in a second, independent sample, where gene expression was measured using 
absolute mRNA values, a reliable quantitation of number of mRNA molecules (Cattaneo et al., 
2016). 
    
Utilizing the GENDEP trial cohort, 86 genes in the inflammatory cytokine pathway were 
investigated by Powell et al (2013b). This showed no significant reductions in transcription of IL-
1-b, IL-6, TNF or MIF or any other of the 86 genes investigated in the cytokine pathway, 
following escitalopram treatment for 8 weeks. They did find significant increase in transcription 
of the cell transporter protein ABCF1 following treatment; this protein has been associated with 
regulation of inflammatory cytokines.  Increase in ABCF1 transcription was also associated with 
treatment response. SSRI treatment response was also investigated by Mamdani et al (2011) 
who found that response to treatment with citalopram is correlated with an increase in interferon 
regulatory factor 7 (IRF7) expression, a transcription factor that regulates interferon-alpha. The 
authors also examined prefrontal cortex tissue from post-mortems of men who had died during 
a depressive episode, and found decreased expression of IRF7. 
 
Guilloux et al (2014) had two major findings: that genes and transcription factors for immune 
and inflammation functions are upregulated in MDD patients, and that a 13 gene model predicts 
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non-remission following antidepressant treatment. This model was successfully applied in both 
their own and a validation cohort, and genes in this group included Interferon induced 
transmembrane protein 3 (IFITM3) and the T-cell surface glycoprotein CD3D. Another study 
found increased baseline TNF expression in MDD and BPD patients vs healthy controls; 
pathway analysis revealed a network centred around TNF expression. (Savitz et al., 2013). 
 
Using both GWAS and a candidate gene approach, Hori et al (2016) found 317 upregulated 
genes in MDD patients that were enriched for a synaptic transmission pathway and a protein-
protein interaction network. This pathway echoes some of the same calcium-signalling genes 
(CACNA1B, CACNA1E) found by the PGC study (CACNA1C and CACNB2) (Ripke et al., 
2012). In candidate analyses, Hori et al‘s most important genes were VAMP2 (vesicle-
associated membrane protein 2), CSGALNACT1 (chondroitin sulfate N-
acetylgalactosaminyltransferase 1, transcript variant 2), and the corticotropin-releasing hormone 
receptor, CRHR2, which showed the largest difference between patients and control.  
 
An opposing result was found by Belzeaux (2012) in a small study (16 patients, 13 controls) in 
which IL-1b and TNF transcription upregulation were linked to increased treatment response, 
and the authors suggested could be used as predictive of treatment response. Belzeaux et al 
(2014) went on to produce an intriguing case report of expression measurement, noting an 
interesting pattern of expression of TNF-α while monitoring a single episode of MDE from 
presentation to treatment and finally resolution. They also found that this TNF-α expression is 
linked to a protein (S100A10) regulating cerebral serotonin-signalling. Mehta et al (2013) also 
found that increased TNF mRNA at baseline was associated with treatment response, but in this 
case it was response to the anti-inflammatory, infliximab. Important negatives were also found 
by Spijker et al (2010) in which LPS-stimulated blood gene expression was used to examine the 
difference between MDD patients and controls: both groups show high expression of TNF, IL-1, 
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IL-6 and IL-10 genes in response to the insult, but with no significant difference between 
patients and controls. 
 
Measuring monocyte-only expression, Carvalho et al (2014) found many inflammatory genes 
that are up-regulated in MDD patients compared to controls, and that expression of MCP1 
(CCL-2) and IL-1B are (negatively) correlated with serum levels. The study also reports that 
elevated IL-8 serum levels are correlated with reduced expression of the glucocorticoid receptor 
alpha mRNA, supporting the hypothesis of an interaction between the hypothalamus-pituitary-
adrenal axis and immune system. They also found that serum IL-6, IL-8 and MCP1 levels are 
significantly increased in MDD patients compared to controls. 
 
Some studies have again used hepatitis C patients following interferon/ribavirin-associated 
depression as a model of inflammation-related depression. Pawlowski et al (2014) found that 
increased expression of several cytokines, including IL-8, IL-10, IL-12, TNF-alpha and IFN-beta, 
are associated with depression.   
 
Transcriptomics studies 
Two genome-wide transcription studies (Morag et al., 2011, Oved et al., 2012) initially found the 
neural cell adhesion molecule L-1-like protein (CHL-1) to be a potential biomarker for 
depression. In an analysis of 463 patients and 459 controls Mostafavi et al (2013) detected a 
significant association between MDD and the interferon α/β signaling pathway, via the 
upregulation of IFN-stimulated gene factor 3 (ISGF3) induced genes. These studies were 
followed by the largest gene expression study to date (Jansen et al. 2015). They identified 13 
clusters associated with MDD. The most statistically significant cluster involved genes enriched 
for the 'IL-12-mediated signaling events‘ and the 'Natural killer cell mediated cytotoxicity‘ 
pathways. Another significant cluster was enriched with the 'Signaling by interleukins' and 'IL-6-
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mediated signalling events‘ pathways. Interestingly, they did not find a difference of expression 
between controls and cases for IL-6, CRP or TNF-α serum levels, but did find that one of the 
receptors of TNF-α (TNFRSF10C), MAPK14, the IL-6 receptor and STAT3, were all up-
regulated, confirming an enrichment with genes in the IL-6 signaling pathway. For the authors, 
the combination of up-regulated inflammatory cytokine genes and down-regulated NK cell 
transcription is a confirmation of the immune suppression/hyper-activation theory of MDD. In the 
same study, one gene was found to be statistically significant at the transcriptional level: DVL3, 
whose participation in the evolutionary ancient Wingless-related integration site may be related 
to hippocampal neurogenesis. Similar results were also found in the Young Finns study 
(Elovainio et al,. 2015), which used gene-set enrichment analysis to examine immune/ 
inflammatory pathways associated with depression. The IL-1 pathway is the set most 
associated with depression, followed by the toll-like pathway, NEF protein pathway, the nuclear 
factor kB (NF-kB) pathway, the kinase AKT pathway and the mature B cell antigen receptor 
(BCR) pathway. Finally, Hepgul et al (2016) found that plasma cytokines are not predictive of 
the development of depression, but mRNA gene expression is: in pathway analysis, the study 
found that both oxidative stress pathways and IL-1, IL-6 and IL-8 pathways are associated with 
the development of depression. 
 
CONCLUDING REMARKS 
 
This review synthesizes the current literature on the association between genetic variants 
involved in immune activation and depression‘s risk, severity, and response to antidepressants. 
Understanding how genetic variants influence the immune system‘s contribution to the 
development of depression is important for the identification of vulnerable individuals, for 
establishing clinical biomarkers and for the development of new pharmaceutical treatments. Our 
results suggest that common genetic variants and gene expression pathways are involved in 
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both immune activation and depression, and we have highlighted some consistent findings 
across the literature. Of note, we have focusses our review on genes relevant to depression, but 
findings relevant to bipolar disorder, schizophrenia and autism, when overlapping with 
depression, have also been reported. It is likely that immune gene variants may be similarly, or 
even more relevant, for these disorders, that have stronger genetic and neurodevelopmental 
influences compared with depression. 
 
Can we identify a consistent pattern of findings? 
 
The most replicated and relevant genetic variants, together with their putative molecular 
mechanisms, are presented in Table 1, and includes polymorphisms in the genes for IL-1b, IL-6, 
IL-10, MCP-1, TNF-a, CRP and PLA2. However, even for the most replicated findings there are 
inconsistent results, both between studies and between the behavioural changes and the 
putative immune mechanisms. For example, within the IL-1b polymorphism in the promoter 
region at position 511, the T/T genotype is considered to be associated with increased secretion 
of IL-1b compared to the C/C genotype (Pociot et al., 1992). However, only two studies found 
evidence for an association of the 511T allele with depressive symptoms ((McCulley et al., 
2004; Rosa et al., 2004), whereas three other studies found that the ‗low IL-1b‘ C allele is 
associated with higher depressive symptoms severity or with earlier age of onset (Fertuzinhos 
et al., 2004; Hwang et al., 2009; Yu et al., 2003a). Similarly, the ‗high TNF-a‘ 308A allele was 
reported as increased in Korean subjects with major depression or with post-stroke depression 
(Jun et al., 2003b; Kim et al., 2011), but in the Caucasian population is the ‗low TNF-a‘ G allele 
that is associated with major depression in the elderly (Cerri et al., 2009).  Similarly, the CRP 
rs1205(G/A) polymorphism, and the A allele of the MCP1 gene, are both the ‗low producing‘ 
alleles, and are both associated with an increase in the risk of depression (Almeida et al., 2009; 
Pae et al., 2004b). The potential molecular and biological correlates of these discrepancies 
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have been discussed extensively before (Bufalino et al., 2013), and it is possible that ‗in vitro‘ 
studies describing the function of a specific polymorphism do not always map onto real 
biological effects. Indeed, these same genetic variants associated with depression also increase 
the risk of inflammation-related metabolic disorders (see below). However, here we want to 
highlight three areas of recent research that may help explaining these discrepant findings.  
 
First, these genetic mechanisms may be relevant only to a subtype of ‗inflammation-related‘ 
major depression, and thus are diluted when analyzed in large pool of depressed patients 
unselected for a specific immunophenotype. The recent study by Raison et al. (2013) on the 
efficacy of infliximab on treatment resistant depression finds that only approximately 30-40% of 
depressed patients (based on the criteria) present with raised inflammatory markers (CRP) at 
baseline, and it is likely that the distribution of high-inflammation genetic variants will be different 
in these patients compared with those with no peripheral inflammation. Indeed, some of the 
most robust findings have been obtained in patients developing depression in the context of 
treatment with interferon-alpha, a widely used model to mimic depression in the context of 
inflammation (see Box 1).  
 
Second, environmental and gene X environment interactions are likely to play a larger role in 
inflammation-related depression than purely genetic mechanisms. For example, previous 
studies and recent meta-analytical evidence show that a history of childhood trauma is 
associated with inflammation in adulthood even in the absence of depression (Baumeister et al, 
2015). Moreover, a number of studies mentioned above have shown that the effects of some 
SNPs may only become evident in the presence of life stressors. For example, Kovács et al. 
(2016a) found that the ‗high IL-1b‘ T allele of rs16944 leads to increased depressive symptoms 
in adult life but only in individuals exposed to childhood trauma, while conferring a weak 
protective effect against depressive symptoms when the individual is exposed to adult life 
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stressors. A paper by Tartter et al. (2015) found instead that the ‗low IL-1b‘ C allele is 
associated with greater depressive symptoms in adulthood following interpersonal stress in 
childhood. Similar gene X environment interactions have been described for the TNF-α and the 
IL-18 genes.  
 
Finally, mRNA gene expression studies have shown more reliable associations with outcomes 
then studies of genetic variants, and indeed have been able to explain the effects of genetic 
variants. For example, Powell et al. (2013a) found that carriers of the A allele of rs1126757 had 
greater reduction in IL-11 levels in response to escitalopram treatment, and that this reduction 
was associated with clinical response. Moreover, the association between increased IL-1b and 
MIF mRNA have been replicated in two independent samples (Cattaneo et al., 2013 and 2016). 
This might be due to the fact that gene expression measurements represent the status of a 
large number of neurobiological systems involved in depression. For example, IL-1b increases 
IDO activity and reduces neurogenesis in experimental models (Zunszain et al., 2012), is 
responsive to a range of antidepressant mechanisms, including nutritional interventions 
(Horowitz et al. 2014),  and contributes to the activation of the inflammasome complex; instead, 
MIF promotes neuroplasticity and neuroprotective processes under physiological conditions, but 
it can also increase the production of pro-inflammatory cytokines under conditions of stress, and 
is modulated by glucocorticoids (Cattaneo et al 2016). Therefore, just measuring two genes can 
give enough information to take the pulse of a host of neurobiological systems. Further -omics 
approaches through GWAs and transcriptomics may finally shed light on the interaction 
between immune genes, immune genes expression and stressful environment in the 
pathogenesis of depression. 
 
Are these genetic variants relevant for mental and physical health? 
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Immune genetic variants that increase the risk of depression are also likely to increase the risk 
of obesity, diabetes, and the metabolic syndrome, and perhaps are contributing to the overlaps 
between depression and these other medical conditions. For example, TNF-a plays an 
important role in insulin governance, and excess secretion can result in insulin resistance; and 
the A allele of the aforementioned TNF-a 308 G/A polymorphism has also been associated with 
type 2 diabetes mellitus, particularly in Asian subjects (Zhao et al., 2013). The -174 G allele of 
the IL-6 gene has been associated with the development of the metabolic syndrome and 
diabetes (Huth et al., 2016) as well as atherosclerosis (Chumaeva et al., 2014) in the context of 
chronic stress. The A allele of the -1082 polymorphism of the IL-10 gene has been associated 
with insulin resistance and obesity (Tarabay et al., 2016). MCP1 is considered to be a major 
attractant for macrophages in obesity, and the A allele of the G-2518 polymorphism is also 
associated with increased risk of diabetes and its complications (Zhang et al., 2011). Therefore, 
immune genes variants that increases the risk of depression also have widespread effects on 
behavior and biological activity, beyond the simple defense against infection, and these effects 
may be physiologically positive or negative, depending on the input of environmental factors and 
the needs of the body. For example, short-term insulin resistance can be an aid to fighting 
infection, and the development of atherosclerosis may be the result of a metabolic system that 
above all else mitigates against hypoglycaemia and its immediate life-threatening 
consequences rather than hyperglycaemia, whose deleterious effects are only seen after many 
years (Kitano et al., 2004).  
 
These conflicting needs of an individual according to the environment could explain why some 
immune genetic variants are still present in the human pool even if they confer risk of both 
depression and metabolic abnormalities (see Figure 1). In a theoretical ancestral setting, ‗at risk‘ 
alleles, such as the TNF-a 308 A allele, may maintain plasma glucose in the harshest of 
conditions, allowing cerebral energy load to be maintained in the face of famine, acute stress 
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(such as attack or flight), and infection. This polymorphism may also interact with the mutually 
reinforcing high-producing IL-6 174 G allele to mount a strong immune response to pathogens, 
and conserve energy via reduced physical activity during acute infection. Similarly, the MCP1 
2518 A allele reduces skeletal muscle uptake of glucose, making more energy available to the 
immune system for infection combat. At the same time, consistently high levels of activity 
employed in foraging and hunting help to keep the excesses of these polymorphisms in check, 
aided by the anti-inflammatory actions of the protective IL-10 1082 G polymorphism.  
 
However, in a modern setting, the sedentary lifestyle, the atmosphere of continuous low-level 
stress, and the tendency towards excess calorie intake, turn these genetic advantages into 
systemic millstones.  Depression and stress activate the immune system, engaging these 
polymorphisms tendencies to raise blood sugars. Deprived of the anti-inflammatory effects of 
exercise, the IL-10 1082 G polymorphism loses its protective influence (and the A allele 
increases the risk of depression). Excess calorie intake creates more adipocytes, and the 
increased TNF-a production (via the 308 A allele) creates insulin resistance, that in the short-
term protects adipocytes from having to absorb excessive, toxic levels of glucose, but in the 
long-term leads to chronic elevated blood sugar and its diabetic consequences. Excess 
adipocytes also means excess MCP1, which recruit further macrophages to adipose tissue, 
which in turn secrete further TNF-a, creating a downward self-reinforcing, obesogenic, diabetic, 
pro-atherosclerotic system whose ultimate result is the metabolic syndrome and cardiac 
disease. 
 
Conclusions 
 
While it is difficult (and perhaps unwise) to wish for a return to an ancestral setting, nevertheless 
the powerful ability of the environment in shaping the effects of genetic variants is an important 
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reminder that the trajectory of our mental and physical health is not deterministically defined. 
We believe that a framework linking stress, immune system and health, not only generates 
meaningful theoretical models, but also can be the focus of environmental interventions that 
bring together nutritional and psychosocial approaches with novel pharmaceutical tools. 
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BOX 1 
IFN-alpha induced depression has been one of the most useful models with which to examine 
the effects of the inflammatory process on mood disorder, with one in four patients experiencing 
depression during treatment. IFN-alpha stimulates IFN-gamma, which in turn induces IDO, an 
enzyme that converts tryptophan into the kynurenine pathway (leading to neurotoxic and 
depressogenic metabolites) rather than towards the production of serotonin. Interestingly, a 
number of immune genes have been described as associated with the risk of IFN-alpha-induced 
depression. Using these model, there is clear and consistent evidence that genetic variants 
associated with increased immune activation are also associated with increased risk of 
depression. For example, in the first such study, Yoshida et al (2005) find that a polymorphism 
(5/14 genotype) in the IFNAR1 interferon receptor that confers higher immunologic activity is 
associated with more depressive symptoms. Interestingly, the authors also find that this gene 
increased viral response to the IFN-alpha therapy, thus describing a genetic association 
between depression and increased immune clearance. Indeed, Lotrich et al. (2011) investigate 
a polymorphism (rs1297860 C/T) in the IL-28b gene, normally associated with viral response, 
and find that The C allele is associated with better viral clearance worse and with somatic 
symptoms of depression. Oxenkrug et al (2011) found that carriers of a high producing 
polymorphism of IFN-gamma (rs2430561) are more likely to suffer depression during IFN-α 
treatment. Smith et al (2011) found a polymorphism of the IDO 1 gene (rs9657182) that 
increases the enzymatic activity and is also associated with depression. Su et al (2010) found 
that polymorphisms in the COX2 (rs4648308) and PLA2 (BanI) genes are associated with 
reduced levels of polyunsaturated fatty acids (PUFAs) during IFN-α treatment. PUFAs have 
been associated with protection against cytokine-induced depression, and therefore this study 
identifies a putative molecular mechanism through which a genetic variants may indirectly 
increase inflammation-induced depression through a reduction in the endogenous anti-
inflammatory PUFAs levels. Indeed, the same authors followed-up their research with a clinical 
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trial where they administered PUFAs as oral supplement prophylactically before starting IFN-
alpha, and were able to drastically delay the onset and reduce the overall rates of depression 
(Su et al., 2014). IFN-alpha also stimulates IL-6 production, and two independent studies find 
that a polymorphism (rs1800795) conferring increased IL-6 activity in response to an immune 
challenge is associated with more severe depressive symptoms (Bull et al., 2009, Udina et al., 
2013).  
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FIGURE 1 LEGEND  
 
 
The conflicting needs of an individual according to the environment could explain why some 
immune genetic variants are still present in the human pool even if they confer risk of both 
depression and metabolic abnormalities. In a theoretical ancestral setting, ‗at risk‘ 
polymorphisms, such as the TNF-a 308 A allele, may maintain plasma glucose in the harshest 
of conditions, allowing cerebral energy load to be maintained in the face of famine, acute stress 
(such as attack or flight), and infection. This polymorphism may also interact with the mutually 
reinforcing high-producing IL-6 174 G allele to mount a strong immune response to pathogens, 
and conserve energy via reduced physical activity during acute infection. Similarly, the MCP1 
2518 A allele reduces skeletal muscle uptake of glucose, making more energy available to the 
immune system for infection combat. At the same time, consistently high levels of activity 
employed in foraging and hunting help to keep the excesses of these polymorphisms in check, 
aided by the anti-inflammatory actions of the IL-10 1082 ‗protective‘ G polymorphism. However, 
in a modern setting, the sedentary lifestyle, the atmosphere of continuous low-level stress, and 
the tendency towards excess calorie intake, turn these genetic advantages into systemic 
millstones, creating a downward self-reinforcing, obesogenic, diabetic, pro-atherosclerotic 
system whose ultimate result is the metabolic syndrome and cardiac disease. 
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Gene Polymorphism Potential Mechanism Finding Sample Size Authors
IL-1b rs16944 The C allele is the 'low-producer'; this may be mediated by strong linkage 
disequilibrium with a TATA box polymorphism at position -31 from the the IL-
1 gene which influences DNA/ protein interactions.
The C allele has been associated with an earlier age of onset of depression, higher depression severity, 
greater depression when exposed to stress, dysthymia, and a lower response to SSRI treatment .
6 papers 
totalling 1733 
patients and 
controls
Hwang et al., 2009, Yu 
et al., 2003a, Tadic et 
al. 2008,  Fertuzinhos 
et al., 2004, Tartter et 
al., 2015, Baune et al., 
2010
IL-6 rs1800795 This SNP is in the promoter region of the IL-6 gene. The G allele is 
associated with higher plasma concentration of  IL-6 than the C allele. The G 
allele has been extensively linked with diabetes and heart disease.
Homozygosity for GG has been associated with greater depressive symptoms during interferon-alpha 
treatment. In breast cancer patients, it is linked with subsyndromal depression and a cluster of fatigue, 
pain, sleep disturbance and depression. It has also been found to act differently according to age, 
mitigating inflammation in adolescence but increasing the chances of depression in adult life.
4 papers 
covering 5738 
patients
Bull et al. (2009), 
Udina et al (2013), 
Roetker et al (2012), 
Tartter et al (2015)
IL10 -1082A IL-10 is an anti-inflammatory cytokine, and inhibits the production of pro-
inflammatory TH1 cytokines, such as IL-6 and IFN-gamma. The A allele is 
considered to be 'low-producing'.
The low producing AA genotype is associated with major depressive disorder, any type of depression 
following-stroke, and depressive symptoms in patients with end-stage renal disease.
3 papers 
covering 1015 
patients and 
controls
Clerici et al., 2009, 
Kim et al., 2011, 
Holtzman et al 2012
MCP-1 G-2518A Also known as chemokine (C-C motif) ligand 2 (CCL-2), MCP1 attracts 
peripheral monocytes to the brain, resulting in an inflammatory reaction. The 
A allele is considered the ‘low producing’.
The A allele is associated with an increased risk of developing both MDD and bipolar depression, and 
with an increased risk of psychotic features and of suicide attempts.
Two papers 
covering  461  
patients and  
controls 
Pae et al., 2004b; 
Altamura et al. 2010
TNF-a rs1800629 The common G allele is a 'low-producer' compared with the rarer AA 
genotype. 
The GG genotype was associated with depression, major depression in the elderly and depression within 
the context of bipolar disorder.
Three papers 
including 749 
patients, 
caregivers and 
controls 
Clerici et al. 2009, 
Cerri et al., 2009, 
Dunn et al., 2013
CRP rs1205 CRP is a marker of inflammation and its synthesis is driven by IL-6. The A 
allele has been correlated with lower circulating CRP levels.
The A allele has been associated with more severe depression, anxiety, and adolescent emotional 
difficulties.
Four papers 
covering 7428 
individuals
Halder et al., 2010, 
Almeida et al., 2009, 
Luciano et al., 2010, 
Ancelin et al., 2015
Phospholipase A2 BanI PLA2 is a family of enzymes that liberate free fatty acids from phospholipids, 
which are in turn transferred to the arachidonic acid pathway and result in the 
production of pro- and anti- inflammatory eicosanoids. The GG genotype has 
been associated with higher PLA2 enzyme activity in platelets, and lower 
levels of circulating PUFAs.
Carriers of the G allele of the BanI polymorphism were more likely to suffer from depression (especially 
somatic symptoms) and experience depression during treatment with interferon-alpha.
Two papers 
comprising 3 
distinct samples 
and totalling 
361 Asian 
patients and 
controls
Pae et al., 2004, Su et 
al., 2010
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